On the search for glycated lipoprotein ApoA-I in the plasma of diabetic and nephropathic patients

被引:26
作者
Lapolla, Annunziata [1 ]
Brioschi, Maura [2 ,3 ]
Banfi, Cristina [2 ,3 ]
Tremoli, Elena [2 ,3 ]
Bonfante, Luciana [1 ]
Cristoni, Simone [2 ,4 ]
Seraglia, Roberta [5 ]
Traldi, Pietro [5 ]
机构
[1] Univ Padua, Cattedra Malattie Metab, Dipartimento Sci Met & Chirurg, Padua, Italy
[2] IRCCS, Ctr Cardiol Monzino, Milan, Italy
[3] Univ Milan, Dipartimento Sci Farmacol, Milan, Italy
[4] ISB, Milan, Italy
[5] CNR, ISTM, Padua, Italy
来源
JOURNAL OF MASS SPECTROMETRY | 2008年 / 43卷 / 01期
关键词
nonenzymatic glycation; diabetes; nephropathy; MALDI/MS; 2D gel electrophoresis;
D O I
10.1002/jms.1274
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The analysis of plasma samples from healthy, diabetic and nephropathic subjects was carried out by 2D gel electrophoresis. This approach shows clear differences among the three classes of subjects. In the case of diabetic and nephropathic patients intense spots appear. Their enzymatic digestion followed by matrix assisted laser desorption ionization/mass spectrometry (MALDI/MS) analysis shows that an overexpression of unglycated and glycated ApoA-I is present in both pathological states. Interestingly, this trend is also observed for the retinol-binding protein (RBP). The data obtained can be relevant to assess possible risks associated either with the glycation level of ApoA-I or with the overexpression of RBP. In fact, in the former case possibly a different functionality of the glycated protein is to be expected, reflecting a different efficiency in cholesterol transport. In the latter case, the increase of RBP level can be related to the overweight of the diabetic subjects under investigation: it is known that obesity leads to RBP overexpression. In the case of nephropathic patients, the RBP level increases in parallel with serum creatinin. Copyright (c) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:74 / 81
页数:8
相关论文
共 30 条
[1]   RETRACTED: Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseases (Retracted article. See vol. 115, pg. E6966, 2018) [J].
Ajees, AA ;
Anantharamaiah, GM ;
Mishra, VK ;
Hussain, MM ;
Murthy, HMK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (07) :2126-2131
[2]   The human plasma proteome - History, character, and diagnostic prospects [J].
Anderson, NL ;
Anderson, NG .
MOLECULAR & CELLULAR PROTEOMICS, 2002, 1 (11) :845-867
[3]   LIPOPROTEIN METABOLISM AND RENAL-FAILURE [J].
ATTMAN, PO ;
SAMUELSSON, O ;
ALAUPOVIC, P .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 21 (06) :573-592
[4]   Proteomic analysis of membrane microdomains derived from both failing and non-failing human hearts [J].
Banfi, C ;
Brioschi, M ;
Wait, R ;
Begum, S ;
Gianazza, E ;
Fratt, P ;
Polvani, G ;
Vitali, E ;
Parolari, A ;
Mussoni, L ;
Tremoli, E .
PROTEOMICS, 2006, 6 (06) :1976-1988
[5]   Antiinflammatory properties of HDL [J].
Barter, PJ ;
Nicholls, S ;
Rye, KA ;
Anantharamaiah, GM ;
Navab, M ;
Fogelman, AM .
CIRCULATION RESEARCH, 2004, 95 (08) :764-772
[6]   Apolipoprotein A-1, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome [J].
Batista, MC ;
Welty, FK ;
Diffenderfer, MR ;
Sarnak, MJ ;
Schaefer, EJ ;
Lamon-Fava, S ;
Asztalos, BF ;
Dolnikowski, GG ;
Brousseau, ME ;
Marsh, JB .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2004, 53 (10) :1255-1261
[7]  
CALVO C, 1988, DIABETES METAB, V14, P264
[8]   NON ENZYMATIC GLYCATION OF APOLIPOPROTEIN-A-I - EFFECTS ON ITS SELF-ASSOCIATION AND LIPID-BINDING PROPERTIES [J].
CALVO, C ;
TALUSSOT, C ;
PONSIN, G ;
BERTHEZENE, F .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 153 (03) :1060-1067
[9]  
CALVO C, 1992, EUR J CLIN CHEM CLIN, V30, P3
[10]   INCIDENCE OF CORONARY HEART-DISEASE AND LIPOPROTEIN CHOLESTEROL LEVELS - THE FRAMINGHAM-STUDY [J].
CASTELLI, WP ;
GARRISON, RJ ;
WILSON, PWF ;
ABBOTT, RD ;
KALOUSDIAN, S ;
KANNEL, WB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (20) :2835-2838